Набор скоро начнётся NCT07287813

Extracorporeal Therapy and Therapeutic Drug Monitoring

— Наблюдательное ICU Patients With ECMO And-or RRT and With Gram Negative Infections Susceptible to BL-BLIs

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально: Состояния в реестре: ICU Patients With ECMO And-or RRT and With Gram Negative Infections Susceptible to BL-BLIs. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Италия
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Pharmacokinetics/Pharmacodynamics and Therapeutic Drug Monitoring of Novel β-lactams and β-lactamase Inhibitors in Critically Ill Patients Undergoing Extracorporeal Therapy

Обзор

The aim of this study is to comparatively evaluate serum concentrations of continuously applied antibiotics in ICU patients, with and without ECMO/RRT support.

Подробное описание

Among all patients being treated with new generation antibiotics (beta.lactams and beta-lactamase inhibitors), we will take into consideration the results of those admitted to intensive care units.

Effective antimicrobial treatment is critical to reduce their mortality associated with bacterial sepsis. They often also require extracorporeal supports, such as renal replacement therapy (RRT) and extracorporeal membrane oxygenation (ECMO), for their survival. However, few studies, limited only to some drugs, report the importance of therapeutic drug monitoring for adequate dose adjustment in these particular conditions of extracoporeal support.

The risk of reaching sub therapeutic or toxic levels is quite high, due to possible very significant variations in the pharmacokinetics of the drugs because of their interaction with the various components of the ECMO and RRT devices, the characteristics of the drug itself and the pathophysiological changes of the patients on ECMO and/or RRT.

Primary aim is to evaluate whether the standard prescriptions of beta lactams/beta lactamase inhibitors (BL/BLIs) are adequate to achieve the optimal PK/PD target also for ECMO and RRT (or combined) patients admitted to intensive care unit.

Secondary aims include to evaluate:

* the occurrence of sub-therapeutic and/or toxic drugs levels * the proportion of patients with insufficient drugs levels in different subgroups (i.e., absence of extracorporeal therapy vs. ECMO; absence of extracorporeal therapy vs. RRT, absence of extracorporeal therapy vs ECMO and RRT) - the proportion of patients with toxic or sub-therapeutic drugs levels in the same subgroups; * the proportion, when possible, of drugs level before and during the extracorporeal therapy, for the same patient; * the occurrence of drug resistance by pathogens and their mechanism

Первичные конечные точки

Primary aim [Срок оценки: up to 24 months]

Вторичные конечные точки (5)

occurrence of sub-therapeutic and/or toxic drugs levels [Срок оценки: up to 24 months]
proportion of patients with insufficient drugs levels in different subgroups [Срок оценки: up to 24 months]
proportion of patients with toxic or sub-therapeutic drugs levels in the same subgroups [Срок оценки: up to 24 months]
proportion, when possible, of drugs level before and during the extracorporeal therapy, for the same patient [Срок оценки: up to 24 months]
occurrence of drug resistance by pathogens and their mechanism [Срок оценки: up to 24 months]

Критерии участия

Критерии включения

adult patients (age 18y or older)
admitted to ICU
supported or not-supported with extracorporeal membrane oxygenation (ECMO) and/or renal replacement therapy (RRT)
affected by gram-negative bacterial infections susceptible to the novel antibiotics.